HN1999000029A - Combinaciones de estatina-inhibidor de mmp. - Google Patents

Combinaciones de estatina-inhibidor de mmp.

Info

Publication number
HN1999000029A
HN1999000029A HN1999000029A HN1999000029A HN1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A HN 1999000029 A HN1999000029 A HN 1999000029A
Authority
HN
Honduras
Prior art keywords
mmp inhibitor
statin
inhibitor combinations
combination
ldl
Prior art date
Application number
HN1999000029A
Other languages
English (en)
Inventor
Warner Lambert Company
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HN1999000029A publication Critical patent/HN1999000029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA COMBINACION DE UN COMPUESTO DE ESTATINA, QUE SE SABE QUE CAUSA UNA REDUCCION EN LOS NIVELES PLASMATICOS DE COLESTEROL LIPOPROTEINAS DE BAJA DENSIDAD (LDL), Y UN INHIBIDOR DE MMP, QUE REDUCE LA RUPTURA DE TEJIDOS CONECTIVOS. LA COMBINACION ES UTIL PARA TRATAR TRASTORNOS VASCULARES Y PREVENIR LA INSUFICIENCIA CARDIACA.
HN1999000029A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp. HN1999000029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
HN1999000029A true HN1999000029A (es) 1999-09-29

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000029A HN1999000029A (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp.

Country Status (18)

Country Link
EP (1) EP1063991A1 (es)
JP (1) JP2002506818A (es)
KR (1) KR20010041916A (es)
AR (1) AR018113A1 (es)
AU (1) AU1591699A (es)
BR (1) BR9815745A (es)
CA (1) CA2309588A1 (es)
CO (1) CO5070670A1 (es)
GT (1) GT199900039A (es)
HN (1) HN1999000029A (es)
MY (1) MY140504A (es)
NZ (1) NZ505994A (es)
PA (1) PA8469001A1 (es)
PE (1) PE20000348A1 (es)
SV (1) SV1999000026A (es)
UY (1) UY25436A1 (es)
WO (1) WO1999047138A1 (es)
ZA (1) ZA992106B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
RU2410118C2 (ru) 2004-12-15 2011-01-27 Зольвай Фармасьютиклз Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611410A (pt) * 1995-11-02 1999-01-05 Warner Lambert Co Método e composição farmacêutica para regular a concentração de lipídios
PL186416B1 (pl) * 1996-05-17 2004-01-30 Warner Lambert Co Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek
IL128545A0 (en) * 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
PA8469001A1 (es) 2002-09-17
AU1591699A (en) 1999-10-11
CA2309588A1 (en) 1999-09-23
BR9815745A (pt) 2000-11-14
NZ505994A (en) 2003-10-31
JP2002506818A (ja) 2002-03-05
SV1999000026A (es) 2000-01-18
UY25436A1 (es) 2001-10-25
CO5070670A1 (es) 2001-08-28
GT199900039A (es) 2000-09-06
KR20010041916A (ko) 2001-05-25
ZA992106B (en) 1999-09-30
MY140504A (en) 2009-12-31
AR018113A1 (es) 2001-10-31
WO1999047138A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03
PE20000348A1 (es) 2000-05-22

Similar Documents

Publication Publication Date Title
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
ES2178298T3 (es) Compuestos anti-inflamatorios.
ES2188285T3 (es) Combinaciones de inhibidores del transporte de acidos biliares ileales y derivados de acido nicotinico para indicaciones cardiovasculares.
NO20033358D0 (no) Kombinasjoner av sterolabsorpsjonsinhibitor og kardiovaskul¶re midler for behandling av vaskul¶re lidelser
UY25268A1 (es) Inhibicion de la oxidacion de lipoproteinas
GT199800134A (es) Terapia de combinacion.
UY25299A1 (es) Combinaciones de estatina-eter carboxialquílico
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PT1140181E (pt) Terapia de combinacao de radiacao e um inibidor de cox-2 para o tratamento da neoplasia
PA8452701A1 (es) Agonistas de prostaglandinas
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
EP0793489A4 (en) AGENTS FOR TREATING SKIN DISEASES
HN1999000029A (es) Combinaciones de estatina-inhibidor de mmp.
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
BR0213181A (pt) Combinações de inibidor de cox-2
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
ES2152107T3 (es) Uso de polisacaridos sulfatados en el tratamiento de heridas cronicas.
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
ATE299703T1 (de) Mmp-hemmer bei bindegewebserweichung
SV2004000109A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv
PA8436301A1 (es) Compuestos de amonio cuaternario
ES2192703T3 (es) Compuestos heterociclicos de guanidinilamino utiles como agonistas alfa-2 adrenoceptores.